Spyre Non Current Liabilities Total vs Total Current Liabilities Analysis
| SYRE Stock | 19.70 1.33 7.24% |
Spyre Therapeutics financial indicator trend analysis is much more than just breaking down Spyre Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Spyre Therapeutics is a good investment. Please check the relationship between Spyre Therapeutics Non Current Liabilities Total and its Total Current Liabilities accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.
Non Current Liabilities Total vs Total Current Liabilities
Non Current Liabilities Total vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Spyre Therapeutics Non Current Liabilities Total account and Total Current Liabilities. At this time, the significance of the direction appears to have strong relationship.
The correlation between Spyre Therapeutics' Non Current Liabilities Total and Total Current Liabilities is 0.78. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Spyre Therapeutics, assuming nothing else is changed. The correlation between historical values of Spyre Therapeutics' Non Current Liabilities Total and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Spyre Therapeutics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Non Current Liabilities Total i.e., Spyre Therapeutics' Non Current Liabilities Total and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | 0.78 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Non Current Liabilities Total
Total Current Liabilities
Total Current Liabilities is an item on Spyre Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Spyre Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Spyre Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Spyre Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.At present, Spyre Therapeutics' Sales General And Administrative To Revenue is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 80.7 M, whereas Tax Provision is projected to grow to (22.2 K).
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Income | 837K | 6.1M | 7.1M | 7.4M | Net Interest Income | 837K | 6.1M | 7.1M | 7.4M |
Spyre Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Spyre Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Spyre Therapeutics fundamental ratios Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 161.6M | 109.9M | 71.1M | 341.9M | 393.1M | 412.8M | |
| Other Current Liab | 464K | 14.0M | 12.8M | 31.1M | 35.7M | 37.5M | |
| Total Current Liabilities | 16.4M | 20.1M | 14.7M | 32.0M | 36.8M | 18.7M | |
| Total Stockholder Equity | 139.8M | 83.9M | 50.3M | 184.0M | 211.6M | 107.9M | |
| Property Plant And Equipment Net | 1.0M | 7.2M | 9.9M | 8.4M | 6.7M | 0.0 | |
| Net Debt | (84.6M) | (10.1M) | (30.2M) | (104.3M) | (188.9M) | (179.4M) | |
| Retained Earnings | (276.0M) | (341.8M) | (425.6M) | (764.4M) | (688.0M) | (653.6M) | |
| Accounts Payable | 2.3M | 3.3M | 677K | 896K | 1.0M | 1.5M | |
| Cash | 90.1M | 15.1M | 34.9M | 188.9M | 217.2M | 228.1M | |
| Non Current Assets Total | 11.8M | 11.0M | 8.9M | 331K | 380.7K | 361.6K | |
| Non Currrent Assets Other | 115K | 842K | 683K | 9K | 331K | 282.7K | |
| Cash And Short Term Investments | 146.3M | 93.1M | 55.7M | 339.3M | 390.2M | 409.7M | |
| Common Stock Shares Outstanding | 2.1M | 2.6M | 3.4M | 6.9M | 7.3M | 7.7M | |
| Short Term Investments | 56.2M | 78.0M | 20.8M | 150.4M | 172.9M | 181.6M | |
| Liabilities And Stockholders Equity | 161.6M | 109.9M | 71.1M | 341.9M | 393.1M | 412.8M | |
| Non Current Liabilities Total | 5.3M | 5.8M | 6.2M | 125.9M | 144.7M | 152.0M | |
| Other Current Assets | 3.5M | 4.9M | 6.2M | 2.3M | 2.6M | 3.3M | |
| Other Stockholder Equity | 415.8M | 425.8M | 476.0M | 763.2M | 877.7M | 921.6M | |
| Total Liab | 21.8M | 26.0M | 20.8M | 157.8M | 181.5M | 190.6M | |
| Total Current Assets | 149.8M | 98.9M | 62.3M | 341.5M | 392.8M | 412.4M | |
| Accumulated Other Comprehensive Income | 11K | (20K) | (48K) | 302K | 347.3K | 364.7K | |
| Short Long Term Debt Total | 5.4M | 5.1M | 4.6M | 84.6M | 97.2M | 102.1M | |
| Net Invested Capital | 139.8M | 83.9M | 50.3M | (911K) | (819.9K) | (778.9K) | |
| Net Working Capital | 133.3M | 78.7M | 47.6M | 309.6M | 356.0M | 373.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.